Compare DexCom, Inc. (DXCM) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs PAGSEG Inc — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while PAGSEG Inc trades at $11.16 (market cap $2.94B). The key difference: DexCom, Inc. is far larger — about 10.8× PAGSEG Inc's market cap, and PAGSEG Inc pays a 10.49% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and PAGSEG Inc for 26 Days on average.
| DXCM | PAGS | |
|---|---|---|
Market Cap | $31.86B | $2.94B |
Volume | 3,607,070 | 4,242,708 |
Sector | Health | Industrials |
52-Week High | $92.34 | $12.00 |
52-Week Low | $54.84 | $8.44 |
Typical Hold Time | 62 Days | 26 Days |
Enterprise Value | $31.32B | $11.02B |
Dividend Yield | — | 10.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
PAGS trades at $11.16, up 6.18% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 7.1 and net income margin of 10.45%. Recent Q2 2026 earnings beat expectations at $0.41 per share. The company maintains a dividend yield with a $0.28 payment scheduled for September 2026. Revenue growth remains stable at $20.6B for 2026 with improving profitability.
PAGS presents a compelling value opportunity with attractive valuation multiples and consistent earnings performance. Key risks include competitive pressures in digital banking and macroeconomic sensitivity in Brazil. Analyst consensus is strongly bullish with 15 buy ratings and a $10.70 price target, though the current price exceeds this target, suggesting potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
